Winner
Managing DVT in the Community - A Service Redesign
Summary of work
Deep Vein Thrombosis (DVT) and pulmonary embolism (PE) cost the NHS hundreds of millions of pounds a year, lead to tens of thousands of hospital admissions and rates are likely to increase. With the introduction of Novel Oral Anticoagulants (NOACs), it is much easier to treat these common and costly conditions in a primary care setting. Despite NICE advocating service redesign and patient access to these novel treatments, uptake has been slow.
The ‘Managing DVT in the Community - A Service Redesign’ campaign was instrumental in sharing best practice and adopting the appropriate support to create primary care pathways for the treatment of DVT, meaning enhanced patient outcomes and savings for the NHS.
Bayer worked with pioneers in the NHS who were the first to implement changes to DVT pathways and implement a behavioural change programme to encourage further changes to DVT pathways throughout the UK.
To date, approximately 50 NHS Trusts have implemented changes to their pathways for the treatment of DVT allowing patient access to Xarelto® in a primary care setting. There is still work to be done, however, these service redesigns are showing real cost savings to the NHS and better quality of life for patients.
Judges’ comments
This was a comprehensive programme on service redesign that translated into really tangible outcomes and introduced new pathways of care, saved the health service money and improved patient outcomes. In all of its pilots a demonstrable number of patients avoided hospitalisation. Bayer showed that they are doing their best to change the way patients are treated - a tough ask in the current environment.
